[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336810-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336810-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pilot-study-of-lung-cancer-screening-for-survivors-of-hodgkin-lymphoma","Pilot study of lung cancer screening for survivors of Hodgkin lymphoma","","Hodgkin lymphoma (HL) survivors face an increased risk of lung cancer, yet most are not eligible for existing lung cancer screening programs used in the general population and the utility of such programs has not been established for this group. A pilot low-dose computed tomography (LDCT) screening study evaluated uptake, participant characteristics, the impact of a decision aid, and screening findings in eligible HL survivors treated at least five years earlier.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pilot-study-of-lung-cancer-screening-for-survivors-of-hodgkin-lymphoma/336810/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pilot-study-of-lung-cancer-screening-for-survivors-of-hodgkin-lymphoma/336810.png","ImageObject",300,407,{"name":42,"@type":43},"Rowan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why was this lung cancer screening pilot needed for Hodgkin lymphoma survivors?","Question",{"text":63,"@type":64},"HL treatment increases lung cancer risk, but most survivors do not meet eligibility criteria for general-population screening and the benefit of these programs in HL survivors had not been tested.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Who was eligible for the pilot and how were participants identified?",{"text":68,"@type":64},"Participants were identified from a lymphoma follow-up database and invited if they had a history of HL with no relapse within 5 years, were aged 18–80, had relevant prior treatments (thoracic radiation and/or procarbazine/mustine chemotherapy), and lived within 40 miles of the Christie hospital.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key baseline LDCT results and follow-up outcomes?",{"text":72,"@type":64},"Among screened participants, baseline LDCT showed negative, indeterminate, and positive findings; additional 3-month surveillance scans identified further positive results. Of four positive scans, two patients were diagnosed with small-cell lung cancer and one underwent curative surgery.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336810,1790535866,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":116,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","ARTICLE-Hodgkin Lymphoma  \nPilot study of lung cancer screening for survivors of Hodgkin lymphoma  \nRachel Broadbent,1,2,3 Philip Crosbie,4,5 Christopher J. Armitage,3,6,7 Ben Taylor,2 Sean Tenant,2 Joseph Mercer,2 John Radford8 and Kim Linton8  \n1 University of Manchester, Division of Cancer Sciences; 2The Christie NHS Foundation Trust; 3 NIHR Greater Manchester Patient Safety Translational Research Center, University of Manchester; 4 Manchester Thoracic Oncology Center, North West Lung Center, Manchester University NHS Foundation Trust; 5 University of Manchester, Division of Infection, Immunity and Respiratory Medicine; 6 Manchester Center for Health Psychology, Division of Psychology and Mental Health, University of Manchester; 7 Manchester University NHS Foundation Trust, Manchester Academic Health Science Center and 8 Manchester Cancer Research Center, Division of Cancer Sciences, Manchester, UK  \nAbstract  \nCorrespondence: R. Broadbent  \n[Rachel.broadbent1@nhs. net](Rachel.broadbent1@nhs. net)  \n[Received:](Received: April 12)[ April 12](Received: April 12), 2023.  \nAccepted: November 8, 2023.  \nEarly view: November 16, 2023.  \n[https://doi.org/10.3324/haematol.2023.283287](https://doi.org/10.3324/haematol.2023.283287)  \nPublished under a CC BY license   \nHodgkin lymphoma (HL) treatment increases the risk of lung cancer. Most HL survivors are not eligible for lung cancer screening (LCS) programs developed for the general population, and the utility of these programs has not been tested in HL survivors. We ran a LCS pilot in HL survivors to describe screening uptake, participant characteristics, impact of a decision aid and screen findings. HL survivors treated ≥5 years ago with mustine/procarbazine and/or thoracic radiation, were identified from a follow-up database and invited to participate. Participants underwent a low-dose computed tomography (LDCT) reported using protocols validated for the general population. Two hundred and eighteen individuals were invited, 123 were eligible, 102 were screened (58% response rate): 58% female, median age 52 years, median 22 years since HL treatment; 91.4% were deemed to have made an informed decision; participation was not influenced by age, sex, years since treatment or deprivation. Only three of 35 ever-smokers met criteria for LCS through the program aimed at the general population. Baseline LDCT results were: 90 (88.2%) negative, ten (9.8%) indeterminate, two (2.0%) positive. Two 3-month surveillance scans were positive. Of four positive scans, two patients were diagnosed with small-cell lung cancer; one underwent curative surgery. Coronary artery calcification was detected in 36.3%, and clinically significant incidental findingsin 2.9% . LDCT protocols validated in ever-smokers can detect asymptomatic early-stage lung cancers in HL survivors. This finding, together with screening uptake and low false positive rates, supports further research to implement LCS for HL survivors (clinicaltrials gov. Identifier: NCT04986189.) .  \nIntroduction  \nTwo large randomized trials established low-dose computed tomography (LDCT) screening for early detection of asymptomatic lung cancer in the ever-smoking general population. The National Lung Cancer Screening Trial (NLST) which randomized ever smokers aged 55-74 to either a chest radiograph or a LDCT scan of the thorax, reported a 20% reduction in lung cancer mortality in the LDCT arm 1 The NELSON (Nederlands–Leuvens Longkanker Screenings Onderzoek) trial randomized ever-smokers aged 50-75 to LDCT screening versus no screening and reported a reduction in lung cancer mortality of 24% in men and 33% in women.2 Following the successful roll-out of ‘Lung Health Checks’ in England3 incorporating lung cancer screening for those at high risk, in September 2022 the UK National Screening Committee recommended a national  \nlung cancer screening program. People aged 55-74 who are at risk of lung cancer due to smoking are eligible for screening if the","cbCaiiyIvC05mbQ4","https://ap.wps.com/l/cbCaiiyIvC05mbQ4","pdf",2283569,"English","# Abstract\n## Methods\n### Patients\n### Study procedures","[{\"question\":\"Why was this lung cancer screening pilot needed for Hodgkin lymphoma survivors?\",\"answer\":\"HL treatment increases lung cancer risk, but most survivors do not meet eligibility criteria for general-population screening and the benefit of these programs in HL survivors had not been tested.\"},{\"question\":\"Who was eligible for the pilot and how were participants identified?\",\"answer\":\"Participants were identified from a lymphoma follow-up database and invited if they had a history of HL with no relapse within 5 years, were aged 18–80, had relevant prior treatments (thoracic radiation and/or procarbazine/mustine chemotherapy), and lived within 40 miles of the Christie hospital.\"},{\"question\":\"What were the key baseline LDCT results and follow-up outcomes?\",\"answer\":\"Among screened participants, baseline LDCT showed negative, indeterminate, and positive findings; additional 3-month surveillance scans identified further positive results. Of four positive scans, two patients were diagnosed with small-cell lung cancer and one underwent curative surgery.\"}]","Pilot study of lung cancer screening for survivors of Hodgkin lymphoma | PDF",1790016697,23,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/de0a4194ebb3adcf2de4805881263038.webp",983,1309,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa59efd900dfc2ce93141f56ddd5956a.webp",982,1308,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c8e352e0518a283d3dc81d67d9e016f.webp",981,1306,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1dca8f702415e80ee4b3ef569694bb2c.webp",980,1305]